超 25 亿美元收购三家 Biotech,阿斯利康收获了什么?

Insight数据库
02 Apr

缺席第一波 CAR-T 盛宴的阿斯利康,正在通过买买买加速进军细胞疗法。近期,阿斯利康宣布,将以10 亿美元收购 EsoBiotec 公司,进一步加码细胞疗法领域。这并非阿斯利康在细胞疗法领域的第一次出手。2024 年初,阿斯利康曾以 12 亿美元收购了亘喜生物。而在 2023 年初,它还以 3.2 亿美元收购了 Neogene 公司。平均每年一次的频繁并购彰显了阿斯利康强化细胞疗法管线的意图。超...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10